PLSE — Pulse Biosciences, Inc.

Pulse Biosciences Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $401,000, primarily from nPulse Catheter and Vybrance disposable sales.
• Cost of Product Revenue: $370,000.
• GAAP Net Loss: $18.6 million, compared to $16.8 million in Q1 2025.
• Non-GAAP Net Loss: $16.4 million, up from $11.4 million year-over-year.
• Cash and Cash Equivalents: $68.3 million as of March 31, 2026, down from $80.7 million at the end of 2025.
• Cash Used in Operating Activities: $14.6 million, slightly higher than $13.5 million in Q1 2025.

2. Strategic Updates and Business Highlights

• Technology Focus: Continued emphasis on the nsPFA (Nanosecond Pulsed Field Ablation) technology, particularly for treating atrial fibrillation (AF).
• Clinical Milestones:
  • Presentation of positive data from a European feasibility study at the AF Symposium and Heart Rhythm 2026.
  • Commencement of the U.S. IDE pivotal study, NANOPULSE-AF, with the first patients enrolled in April 2026.
• Leadership Changes: Appointment of Liane Teplitsky as COO and Dr. David Kenigsberg as CMO to strengthen the executive team.
• Resource Allocation: Strategic realignment to focus resources on the nPulse Cardiac Catheter for AF, with plans to accelerate development and commercialization.

3. Forward Guidance and Outlook

• Enrollment Timeline: Anticipated completion of enrollment for the pivotal study by early Q4 2026, accelerated from the previous end-of-year guidance.
• Regulatory Submissions: CE Mark submission expected in the second half of 2026, with potential approval by mid-2027.
• Market Potential: Continued discussions with potential strategic partners, particularly in the electrophysiology space.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a higher net loss compared to the previous year, raising concerns about financial sustainability.
• Cash Burn: Continued high cash usage in operations, which may necessitate future funding rounds or strategic partnerships to maintain liquidity.
• Patient Population Risks: Potential concerns about enrolling a sicker patient population in the U.S. compared to the European study, which could impact clinical outcomes.
• Adoption Barriers: Challenges in the surgical ablation clamp market due to procedural complexity and low adoption rates of existing devices.

5. Notable Q&A Insights

• Clinical Trial Sites: Approval for up to 30 sites for the pivotal study, with a cap of 15-20% of total enrollment per site to avoid concentration.
• Anesthesia Protocol: General anesthesia is required for the pivotal study, though conscious sedation may be viable in future applications.
• Mapping Technology: The EnSite mapping system is expected to be the primary technology used in the IDE study, enhancing procedural accuracy.
• Market Opportunity for Thyroid Cancer: The addressable market for treating papillary thyroid microcarcinoma is significant, with estimates of 100,000 to 200,000 procedures annually when considering both benign nodules and microcarcinoma cases.

Overall, Pulse Biosciences is at a critical juncture with promising clinical data and strategic realignments, but faces challenges related to financial performance and market adoption.